{"company":{"id":2113487,"name":"Lantheus","domain":"lantheus.com","url":"https://alion.io/company/lantheus"},"section":"news","answer":"Lantheus: 20 headlines on record, 9 headlines in the last 90 days. Its story counts 2 milestones.","figures":[{"label":"Headlines","value":"20"},{"label":"In 90 days","value":"9"},{"label":"Milestones","value":"2"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":7},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":2}],"news":[{"date":"2026-10-04","kind":"News","title":"Lantheus Holdings stock faces an October 14 merger vote","source":"Lantheus Holdings stock faces an October 14 merger vote","url":"https://ad-hoc-news.de/boerse/news/corporate-news/lantheus-holdings-stock-faces-an-october-14-merger-vote/70225220"},{"date":"2026-10-01","kind":"Press release","title":"Rooted in Massachusetts. Built to Advance Patient Care.","source":"bizjournals.com","url":"https://bizjournals.com/boston/press-release/detail/13481/Lantheus"},{"date":"2026-09-30","kind":"Blog","title":"Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY TruVu (piflufolastat F 18)","url":"https://lantheus.com/lantheus-announces-cms-grants-transitional-pass-through-status-for-pylarify-truvu-piflufolastat-f-18/"},{"date":"2026-09-28","kind":"News","title":"Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/lantheus-announces-first-patient-dosed-in-sparrow-phase-2-3-registrational-trial-in-prostate-cancer-1036577581"},{"date":"2026-09-26","kind":"News","title":"Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/lantheus-holdings-lnth-could-7-181003851.html"},{"date":"2026-09-23","kind":"Press release","title":"Lantheus Merger Advances with Renewed Antitrust Review","source":"The Globe and Mail","url":"https://theglobeandmail.com/investing/markets/stocks/LNTH/pressreleases/4742788/lantheus-merger-advances-with-renewed-antitrust-review/"},{"date":"2026-09-22","kind":"Blog","title":"Lantheus Receives Final FDA Approval for BRAVNETSA (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA for the Treatment of GEP-NETs","url":"https://lantheus.com/lantheus-receives-final-fda-approval-for-bravnetsa-lutetium-lu-177-dotatate-the-only-radiopharmaceutical-fda-has-determined-to-be-bioequivalent-and-therapeutically-equivalent-to-lutathera/"}],"story":[{"title":"Team of 1,071 was 813 · US Form 5500 (plan participants)"},{"title":"Acquired SHINE Technologies to Acquire Lantheus · hitconsultant.net","url":"https://hitconsultant.net/2025/05/09/shine-technologies-to-acquire-lantheus-spect-imaging-business/"}],"as_of":"2026-11-21","cite":"Lantheus, News. Alion, Nov 21, 2026. https://alion.io/company/lantheus/news","html_url":"https://alion.io/company/lantheus/news","json_url":"https://alion.io/company/lantheus/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-21T04:37:27Z"}}